

SUBJECT INDEX TO VOLUME 5

<p>ABO-incompatible heart transplantation 223 neonatal tolerance after 226</p> <p>ABO-incompatible infant heart transplantation 223 graft accommodation vs. B cell tolerance in 223 mechanism of 224 neonatal tolerance vs. graft accommodation in 224 targeting antibody-mediated rejection in 223</p> <p>ABO-incompatible kidney transplantation 223 graft accommodation in 223</p> <p>ACAT inhibitor 465 anti-atherogenic effects of in experimental animals 465 liver/intestine as target of 465 macrophages as target of 466</p> <p>ACAT knockout mice 466</p> <p>Acetaminophen (paracetamol) 419 cardiovascular actions of 419,421 future directions for 425 in hypoxia-reoxygenation injury 424 in ischemia-reperfusion injury 422 in myocardial infarction 424 in ventricular arrhythmias 425 <i>in vitro</i> antiarrhythmic actions of 425 mechanisms of action of 419 vascular actions of 421</p> <p>Acute humoral xenograft rejection (AHXR) 203,234</p> <p>Acyl-coenzyme A 463 inhibitors of 463</p> <p>Acyl coenzym A cholesterol acyltransferase (ACAT) 463</p> <p>AIDS associated tumors 337 associated pulmonary hypertension 337 therapies for 338</p> <p>Allotransplantation 206,208 chronic antibody-mediated rejection in 208</p> <p>Alzheimer's disease 467 ACAT inhibitors for 467</p> <p>Angiotensin 392,393 related electrical alterations 392</p> <p>Angiotensin converting enzyme (ACE) inhibitors 15,360,503 animal studies with 506 anti-atherosclerotic effects of 506 combination of 23 effect on plaque progression 506 IMPRESS study for 26 in endothelial dysfunction 506 in essential hypertension 17 in heart failure 20 in high cardiovascular risk patients 22 in hypertension 15 in hypertensive/diabetic patients on macrovascular endpoints 507 in myocardial infarction 21</p>	<p> OVERTURE trial for 26 preventing atherosclerosis with 503</p> <p>Angiotensin II receptor antagonists 17 combination of 23 in essential hypertension 17</p> <p>Angiotensin receptor blockers (ARBs) 509 in prevention of macrovascular disease 509</p> <p>Anti tumor 92 targeted to P2 receptors 92</p> <p>Antibody mediated rejection 199,233,255 accommodation/tolerance in 244 anti-HLA/anti-SLA antibodies in 238 blocking of circulating xenoreactive antibodies in 241 characterization of 237 detection of 199 elicited xenoreactive immune response in 237 endothelial cell activation in 201 endothelial cell death in 201 immunosuppressants in 243 in allotransplantation 206 in discordant xenotransplantation 203 in pig-to-nonhuman primate xenotransplantation models 233 in tissue sections 199 interference with activation of complement cascade in 242 morphology in allotransplantation 206 morphology in discordant xenografts 202 pathological features of 199 removal of antibody target in 258 removal of principal targets of xenoreactive antibodies in 242 removal of xenoreactive antibodies in 241 role of electron microscopy 199 role of immunofluorescence 199 role of light microscopy 199 splenectomy in 243 strategies to prevent 241 thrombogenic events in 260 tunnel method for 200</p> <p>Anti-inflammatory 92 targeted to P2 receptors 92</p> <p>Anti-non-αGal natural antibodies 236</p> <p>Anti-pig antibodies 256 strategies to deplete 256</p> <p>Anti-αGal natural antibodies 236</p> <p>Apolipoproteins 473 atheroprotective effects of HDL 473</p> <p>Apolipoprotein A-1 milano 471 cardiovascular status of 471 clinical data of 476 in atherosclerosis 474 in endothelial function 476 in intimal hyperplasia 473 in restenosis 475</p>
---	---

in thrombosis	475	anti-mitogenic activity of.....	180
in vascular disease	473	anti-proliferative activity of.....	180
limitations of	477	biological properties of	177
Apoptosis	136,145,150,157,392	in cardiovascular system	177
induction in VSMC by statins	136	lipoxygenase inhibiting activity of	180
in neointima-derived VSMC	139	vascular action of	179
role of Ras/Rho proteins in	150	Bile acids	34
Atherogenesis	166	Brugada syndrome (BrS)	409
relevance of NADPH oxidase in	166	cilostazol in	413
Atherosclerosis	165,168,306,433,441,505,543	clinical aspects of	409
animal models of	433,437,543	drug therapy in	409,414
cholesterol hypothesis for	165	ionic basis of	409
distinctions between initiation/progression of	435	ionic basis of pharmacological therapy of	411
endpoint assessment of	435,437	isoproterenol in	413
histopathologic endpoints of	435	mexiletine in	414
imaging of	435	quinidine in	412
in apolipoprotein E deficient mice	433	sotalol in	414
induced by dietary cholesterol	441	Calcium channel blocker	489
<i>in vivo</i> endpoints of	435	evaluation of basic/clinical evidence of	489
interventions in apo E deficient mice	434	rationale for combined therapy of	489
markers of	505	Cancer	3,90
mouse models of	433	CD44 in	4
rabbit models of	436	hyaluronan receptors RHAMM in	4
relevance of NADPH oxidase in	166	P2 receptors in	90
strain-specific development of	433	Cancer metastasis	39
Atherosclerotic disease	431	carbohydrate expression in	53
pharmacological strategies for	431	carbohydrates in	39
prevention of	431	characteristic behavior of tumor cells during	42
Atherosclerotic plaque imaging	561	characterization/identification of behavior of	
Atherosclerotic plaque progression	471	metastatic tumor cells in	39
medications for	471	early foci in	45
pharmacological strategies for	471	fibronectin (FN) in	52
prevention of	471	glycosaminoglycans (GAGs) in	52
role of apoA-1 milano/phospholipid complexes	471	laminin (LN) in	53
ATP binding cassette (ABC) transporters	31	lodgement/extravasation in	45
in biliary metabolism	33	molecular mechanisms of	47
in sterol absorption	31	role of cell adhesion molecules	39
Atrial fibrillation (AF)	387,405	translocation of metastatic cells in	42
anticoagulation clinic for patients with	405	Cardiac hypertrophy	165, 185, 277, 290,328,481
haemodynamic effects of	393	management of	185
to pathophysiology of AF	391	role of endothelial progenitor cell dysfunction	
Atrial fibrosis	392	in	277
Azimilide	75	role of ETS in	290
as novel oral class III antiarrhythmic	75	role of NHE1 in	328
electrophysiology of	76	role of statins in	165
for supraventricular tachyarrhythmias	78	therapeutic strategies in	185
for supraventricular/ventricular arrhythmias	75	Cardiovascular disease	165,185,277,290,481
for ventricular tachyarrhythmias	81	management of	185
mechanism/clinical pharmacology of	76	role of endothelial progenitor cell dysfunction	
β cell tolerance	271	in	277
in transplantation	271	role of ETS in	290
Baicalein	177	role of statins in	165
anti-angiogenic activity of	180	therapeutic strategies in	185
anti-oxidative activity of	177	Cardiovascular medicine	15
anti-platelet aggregating activity of.....	181	angiotensin II inhibition in	15
anti-thrombotic activity of.....	181	in high cardiovascular risk patients	22
		Cardiovascular MRI	561

Cardiovascular risk	379,489	Diabetes	503
integrated perspective on	489	effect on cardiovascular events	508
pre-diabetes state in	379	in prevention of myocardial infarction	508
Carotid intima-media thickness	559	link with cardiovascular disease	503
to monitor atherosclerosis	559	Diabetes-associated atherosclerosis	503
CAT1	463	animal models of	503
development of selective inhibitors for	466	Diabetic atherosclerosis	503
regulation of	463	Direct NO donors	69
tissue distribution of	463	Discordant xenotransplantation	206
CAT2	463	chronic antibody-mediated rejection in	206
development of selective inhibitors for	466	Drug eluting stents	313
regulation of	463	clinical studies of other used in	317
tissue distribution of	463	development of	313
CCBS	492	drawbacks of	318
antioxidant activity of	492	emerging uses of	313
physico-chemical basis for endothelial actions		for treatment of acute myocardial infarction	317
with	492	for treatment of in-stent restenosis	317
Cell cycle regulation	145	in interventional cardiology	313
role of Ras/Rho proteins in	147	Dyslipidemia	169
Cellular differentiation	148	in metabolic syndrome	169
role of Ras/Rho proteins in	148	in type 2 diabetes	169
Cerivastatin	139	Endocannabinoid receptor antagonists	549
Cholesterol	441	for weight reduction	549
in extracellular homeostasis	443	Endocannabinoid system	551
induced inflammation	445	Endothelial dysfunction	490
intracellular synthesis of	441	pharmacologic approaches to	490
uptake of	441	calcium channel blockers in	490
Cholesteryl ester transfer protein (CETP)	481	Endothelial progenitor cells (EPC)	277
from protein to gene	481	as drug target	277
genetically determined deficiency of	482	drug-mediated effects on	279
inhibition of	485	effect on HMG-CoA reductase inhibitors on	279
pharmacological inhibition in man	483	effects of cytokines/growth factors/hormones on	281
role in human lipid metabolism	482	genetic reprogramming of	283
size in	482	Endothelin	292,293
Complement mediated graft injury	199	antagonists for	289
in tissue sections	199	clinical studies of	293
role of electron microscopy	199	in lungs	293
role of immunofluorescence	199	receptors for	288
role of light microscopy	199	Endothelin family	287
tunnel method for	200	alternative pathways to	290
Congestive heart failure	294,384	pathways to inhibit	289
pathophysiological role of ETs in	294	Endothelin receptor antagonists	287
Coronary computed tomography	560	clinical studies of	292
in coronary calcium assessment	560	for cardiovascular diseases	287
of non-calcified atherosclerosis	561	Erythropoietin	355
Coronary plaque imaging	561	antiapoptotic effects of	366
Cross talk	169	anti-inflammatory properties of	366
between angiotensin receptor/insulin receptor		cardioprotection by	365
pathways	169	forms of	356
Cyclooxygenase (COX)	303	in cardiovascular disease	355
activity of	303	in heart failure	355
effect of inhibition on cardiovascular events	307	in hematinic deficiency	359
in atherosclerosis	305	in hematopoietic effect of	355
pathway of	303	in hemodilution	359
vascular function of	305	mechanisms of cardioprotection by	366

pharmacokinetics of	357	Hyaluronan	3
pleiotropic effects of	355,363	as therapeutic targets in cancer	3
proangiogenic effect of	366	in intracellular signaling of	8
protection of vascular integrity by	366	in mitosis	7
recombinant human type of	356	in multiple myeloma	6
therapy in congestive heart failure	360	Hyaluronan synthase	3
Extracellular matrix (ECM) proteins	49	as therapeutic targets in cancer	3,8
Ezetimibe	455	Hyperacute lung rejection	255
cholesterol absorption blockade with	455	antibody depletion in	257
efficacy of	459	as paradigm for dysregulated inflammation	255
Fibrin-platelet thrombi	200	complement inhibition in	258
detection of	200	eicosanoid balance in	259
Gap junctions	393	pathogenesis of	255
Heart failure	328,357	pre-clinical studies of	264
erythropoietin in	357	regulation of complement cascade in	257
in anemia	357	role of thrombin/platelets in	260
neuroprotection by	364	therapeutic targets in	264
role of NHE1 in	328	tissue macrophages in	259
Hepatic/aortic inflammation	444	Hyperacute rejection (HAR)	202
dietary stress to	446	in discordant xenotransplantation	202
markers of	444	Hyperacute rejection (HAR)	234
High density lipoprotein (HDL)	471,581	Hyperlipidemia	489
atheroprotective effects of HDL	473	effect of endothelial dysfunction	489
effect of cholesteryl ester transfer protein		Hypertension	290,489
inhibition	481	effect of endothelial dysfunction	489
mimetic therapy of	477	ET and experimental models of	291
Highly active antiretroviral therapy (HAART)	337	pathophysiological role of ETs in	290
associated metabolic syndrome clinical/		Indirect NO donors	69
therapeutic aspects of	338	Inflammation	89,292
dilated cardiomyopathy by	337	P2 receptors in	89
dysglycemia by	340	Insulin resistance	377
dyslipidemia by	339	in development of diabetes mellitus	378
hypertension by	340	measurement of	378
infective endocarditis by	337	metabolic consequences of	378
molecular mechanisms of associated metabolic		pathogenesis of	378
syndrome by	340	Integrin-mediated adhesion	155
pericardial effusion by	337	disruption of	155
risk of cardiovascular disease by	341	Intracellular acidification	156
HIV infection	337	role of	156
cardiovascular complications of	337	Intravenous immunoglobulin (IVIG)	215
HMG-CoA reductase	441	ABO incompatible transplantation with	219
in cholesterol biosynthesis	441	desensitization with	216
inhibition of	441	modulating alloimmune responses with	215
HMG-CoA reductase inhibitors	441	positive crossmatch transplantation using	217
cholesterol-lowering effect of	447	Islet rejection	239
effects on chronic subacute inflammation	441	controversial role of natural antibodies in	240
mode of action of	443	role anti- α Gal antibodies in	239
pharmacokinetics of	443	role of elicited anti-pig antibodies in	240
Human vascular tone	290	Isoprenoid evolution	116
effects of endothelin in	290	LDL-C	122
Humoral rejection	239	effects on platelet function	122
role in transplantation to primates	239		

Oxidative stress	165,292	edema by	384
endogenous antioxidant systems in	165	effect on atherosclerosis	383
insulin resistance in	169	effect on blood pressure	382
modulators of	165	effect on fibrinolysis	383
NADPH oxidase system in	166	effect on glycemic control	382
role of statins in	165	effect on inflammation	383
vascular oxidase in	165	effect on lipids	382
xanthine oxidase system in	167	in prevention of type 2 diabetes mellitus	383
P2X receptors	87	liver toxicity by	384
P2Y ₁ as	87	mechanism of action of	380
P2Y ₂ as	87	side effects of	384
P2Y ₃ as	88	weight gain by	384
P2Y ₄ as	88	Pravastatin	139
P2Y ₅ as	88	Proinflammatory cytokines	359
P2Y ₆ as	88	Protein prenylation	154
P2Y ₇ as	88	role of	154
P2Y receptors	86	Pudendal vasculature	186
P2Y ₁ as	86	structural basis of resistance in	186
P2Y ₂ as	86	Pulmonary arterial hypertension	293
P2Y ₄ as	86	pathophysiological role of ET in	293
P2Y ₆ as	86	Reactive oxygen species (ROS)	168
P2Y ₁₁ as	86	in endothelial function/dysfunction	168
P2Y ₁₂ as	87	Recombinant erythropoietin	368
P2Y ₁₃ as	87	adverse effects of	368
P2Y ₁₄ as	87	Renal protection	22
Paclitaxel eluting stents	315	angiotensin II receptor blockade in	22
clinical studies of	315	Renin angiotensin system	387,505
Peroxisome proliferator-activated receptors (PPARs)	377,379	electrical/structural remodeling in	388
anti-atherosclerotic activity of	381	electrophysiological properties of	387
Peroxisome proliferator-activated receptor α (PPAR α) ..	513	electrophysiological properties of triggers in	388
and endothelial cells (ECs)	515	Renin angiotensin system blockade	387
and monocytes/macrophages	515	animal studies of	394
and lipoprotein metabolism	516	clinical studies of	395
and T lymphocytes	516	in treatment of atrial fibrillation	387,394
and vascular smooth muscle cells (VSMC)	516	Renin inhibitors	27
animal data of	517	rHuEpo	360
antiatherosclerotic effects of	516	studies with	360
cellular actions of	515	Serum paraoxonase	170
clinical data of	517	Sexual dysfunction	185
human data of	517	antihypertensive therapy for	190
in atherosclerosis	513	current treatment strategies for	188
Physiology	185	etiologies in female	188
of male/female sexual responses	185	etiologies in male	187
Plasmapheresis	215	management of	185
ABO incompatible transplantation with	219	prevalence of	187
modulating alloimmune responses with	215	target for treatment of	190
positive crossmatch transplantation using	217	targeting endothelial dysfunction in	191
Polyreactive antibodies	237	targeting vascular structure for treatment of	191
Porcine islets	239	therapeutic strategies in	185
role in transplantation to primates	239	Sirolimus-eluting stents	315
PPAR α polymorphisms	519	clinical studies of	315
in atherosclerosis	519		
PPAR- γ thiazolidine dione agents	380		
biologic effects of	380		
clinical effects of	382		

Solid organ xenografts	233	Sterol absorption	31
histopathology of	233	ABCG5 in	33
pathogenesis of humorally-mediated rejection of	233	ABCG8 in	33
Spontaneous death receptor clustering	156	Subacute chronic inflammation	444
Statin	115,121,127,145,165,135,489,492	inducers of	444
animal models for	140	markers of	444
antioxidant activity of	492	reduction of	447
cholesterol-independent effects of	127	Thiazolidinediones	377
clinical studies prevention of restenosis	135,141	anti-atherosclerotic activity of	381
effect on cellular differentiation	149	cardiovascular perspective of	377
effect on injury-induced neointima formation	140	in treatment of pre-diabetic/diabetic individuals ..	377
effects on media cells	136	PPAR- γ agonist as	377
effects on oxidative pathways	170	Thrombin	115
endothelial function of	492	cellular mediation of	116
evaluation of basic/clinical evidence of	489	Transplantation	271
in apoptosis	150	humoral response to	271
in atherogenesis	129	humoral tolerance in	272
in atherosclerosis	127	Vascular disease	489
in cell cycle	148	integrated perspective on	489
in diabetic dyslipidemia	171	Vascular network destruction	200
in immunomodulation	127,130	detection of	200
in inflammation	127,129	Vasimibe	467
in metabolic syndrome	171	clinical trials of	467
in plaque stability	130	Vasopeptidase	24
in regulation of PON1	172	Vasopeptidase inhibitors	26
in SMCs migration/proliferation	130	Visceral adipose tissue	345
induced apoptosis	153	compartments of	346
induced vascular smooth muscle cell apoptosis ...	135	imaging of	345
induced VSMC cell cycle arrest	136	ultrasound imaging of	347
LDL reduction by	496	Weight reduction	549
mechanism for antiplatelet action of	121,122	benefits of	549
mechanism of action of	128	use of rimonabant	551
pharmacology of	127	Xenoreactive anti-bodies	235,237,238
rationale for combined therapy of	489	characterization of	235
regulation of cell fate by	145	genetics of	238
related toxicity of	157	Xenoreactive natural antibodies	235
role in myeloperoxidase pathway	171		
to inhibit VSMC proliferation	136		
treatment in humans	121		
Statin-induced apoptosis	155		
mechanisms of	155		
Statin-induced neointimal cell apoptosis	139		
mechanisms for	139		
Stents eluting antirestenotic agents	315		
in clinical practice	315		